Pfizer and BioNTech say a three-shot dose of their COVID-19 vaccine was able to neutralize the new omicron variant in a laboratory test, and that they could deliver an omicron-based vaccine in “MAR 2022 if needed.” In a statement regarding the Pfizer vaccine’s efficacy against Omicron, the companies said the two vaccine doses were less effective in neutralizing the variant compared to three doses. "Ensuring as many people as possible are fully vaccinated with the first two-dose series and a booster remains the best course of action to prevent the spread of COVID-19," Pfizer boss Albert Bourla said. In a later briefing, the companies stressed that their findings are "preliminary," and more research and real-world effectiveness data is needed to inform the best path forward.
You will be redirected in 2 seconds.
CLICK HERE FOR FULL STORY
